(Q36695412)

English

Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis

scientific article published on 29 December 2006

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1 reference

14 August 2023

0 references

Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

chronic obstructive pulmonary disease

1 reference

14 August 2023

randomized controlled trial

1 reference

19 September 2019

1 reference

7 November 2019

Robert A Stockley

1

object named as

Robert A Stockley

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Philip J Whitehead

2

object named as

Philip J Whitehead

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Michael K Williams

3

object named as

Michael K Williams

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

publication date

29 December 2006

4 references

Europe PubMed Central

PMC publication ID

15 August 2017

19 September 2019

7 November 2019

14 August 2023

Respiratory Research

4 references

Europe PubMed Central

PMC publication ID

15 August 2017

19 September 2019

7 November 2019

14 August 2023

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

147

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

1 reference

Europe PubMed Central

14 August 2023

copyright status

0 references

Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Addition of salmeterol to existing treatment in patients with COPD: a 12 month study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Obtaining evidence for use by healthcare payers on the success of chronic obstructive pulmonary disease management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Measuring the success of treatment for chronic obstructive pulmonary disease--patient, physician and healthcare payer perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Interpreting thresholds for a clinically significant change in health status in asthma and COPD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Toward a consensus definition for COPD exacerbations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

A measure of quality of life for clinical trials in chronic lung disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Measurement of health status. Ascertaining the minimal clinically important difference

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1779294

30 September 2017

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-147

21 January 2018

Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-147

21 January 2018

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-147

21 January 2018

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-147

21 January 2018

The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-147

21 January 2018

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-147

21 January 2018

Frequency response of portable PEF meters

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-147

21 January 2018

Cardiovascular safety of salmeterol in COPD.

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-147

21 January 2018

Tolerance to bronchodilating effects of salmeterol in COPD

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-147

21 January 2018

Mortality after hospitalization for COPD.

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-147

21 January 2018

Evaluation of bronchodilator responses in patients with "irreversible" emphysema

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-147

21 January 2018

The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-147

21 January 2018

Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline

1 reference

https://api.crossref.org/works/10.1186%2F1465-9921-7-147

21 January 2018

The St George's Respiratory Questionnaire

1 reference

https://pubmed.ncbi.nlm.nih.gov/17196106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire

1 reference

https://pubmed.ncbi.nlm.nih.gov/17196106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society

1 reference

https://pubmed.ncbi.nlm.nih.gov/17196106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)

1 reference

https://pubmed.ncbi.nlm.nih.gov/17196106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

https://pubmed.ncbi.nlm.nih.gov/17196106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment cost of acute exacerbations of chronic bronchitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17196106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17196106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/17196106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium

1 reference

https://pubmed.ncbi.nlm.nih.gov/17196106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17196106

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1465-9921-7-147

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36695412&oldid=2199199958"